DAWN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Day One Biopharmaceuticals Inc (DAWN) is not a good buy for a long-term beginner investor at this time. The stock is undergoing an acquisition by Servier for $21.50 per share in cash, which caps its upside potential. The technical indicators show an overbought condition, and the recent analyst downgrades reflect the acquisition's fair valuation. Additionally, there are no strong proprietary trading signals for this stock today.
The stock is in an overbought condition with an RSI of 85.885. The MACD histogram is negative (-0.0938) and expanding downward. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its acquisition price of $21.50, limiting further upside. Key support and resistance levels are close to the current price, indicating limited volatility.
The acquisition by Servier for $21.50 per share in cash provides a stable exit point for current investors. The company's revenue increased significantly in Q4 2025, up 83.92% YoY.
Analysts have downgraded the stock to Neutral, reflecting the acquisition's fair valuation. The stock is overbought, and technical indicators suggest limited room for growth.
In Q4 2025, revenue increased by 83.92% YoY to $53.72 million. However, net income dropped by 67.62% YoY to -$21.28 million, and EPS fell by 67.19% YoY to -$0.21. Gross margin also declined slightly to 88.68%.
Analysts have downgraded the stock to Neutral following the acquisition announcement, with a price target of $21.50, reflecting the acquisition price. This indicates limited upside potential.
